Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Glaukos Corporation stock logo
GKOS
Glaukos
$95.38
-1.2%
$95.71
$77.10
$163.71
$5.46B0.78936,970 shs29,444 shs
Penumbra, Inc. stock logo
PEN
Penumbra
$271.49
-0.1%
$246.99
$184.80
$310.00
$10.56B0.4493,452 shs15,055 shs
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$37.33
+0.3%
$32.64
$23.69
$37.65
$16.37B0.68873,832 shs34,044 shs
Solventum Corporation stock logo
SOLV
Solventum
$72.83
+0.2%
$73.77
$60.01
$85.92
$12.64B0.521.08 million shs26,395 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Glaukos Corporation stock logo
GKOS
Glaukos
+1.22%+7.47%+2.81%+2.34%-28.69%
Penumbra, Inc. stock logo
PEN
Penumbra
+1.31%+7.58%+19.43%+1.54%+35.51%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
-0.01%+0.81%+18.01%+28.71%+20.13%
Solventum Corporation stock logo
SOLV
Solventum
-0.39%+1.05%-1.22%-0.53%+20.99%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Glaukos Corporation stock logo
GKOS
Glaukos
4.7294 of 5 stars
4.44.00.04.42.71.70.6
Penumbra, Inc. stock logo
PEN
Penumbra
4.7599 of 5 stars
3.55.00.03.72.22.51.9
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.9524 of 5 stars
1.04.02.50.02.70.03.8
Solventum Corporation stock logo
SOLV
Solventum
1.5004 of 5 stars
3.13.00.00.02.20.00.0
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Glaukos Corporation stock logo
GKOS
Glaukos
2.79
Moderate Buy$127.4233.59% Upside
Penumbra, Inc. stock logo
PEN
Penumbra
2.94
Moderate Buy$300.4710.67% Upside
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
2.00
Hold$36.00-3.55% Downside
Solventum Corporation stock logo
SOLV
Solventum
2.27
Hold$85.7517.74% Upside

Current Analyst Ratings Breakdown

Latest GKOS, SNN, SOLV, and PEN Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2025
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$28.00 ➝ $36.00
8/15/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Zacks Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/8/2025
Solventum Corporation stock logo
SOLV
Solventum
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$75.00 ➝ $79.00
8/8/2025
Solventum Corporation stock logo
SOLV
Solventum
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$87.00 ➝ $94.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price Target$130.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$86.00 ➝ $92.00
7/31/2025
Glaukos Corporation stock logo
GKOS
Glaukos
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$125.00 ➝ $134.00
7/31/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$260.00 ➝ $266.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Set Price TargetBuy ➝ Buy$300.00 ➝ $310.00
7/30/2025
Penumbra, Inc. stock logo
PEN
Penumbra
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$330.00 ➝ $325.00
(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Glaukos Corporation stock logo
GKOS
Glaukos
$383.48M14.26N/AN/A$13.34 per share7.15
Penumbra, Inc. stock logo
PEN
Penumbra
$1.19B8.86$2.94 per share92.47$33.18 per share8.18
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$5.94B2.75$3.16 per share11.80$12.64 per share2.95
Solventum Corporation stock logo
SOLV
Solventum
$8.25B1.53$9.94 per share7.33$21.02 per share3.46
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Glaukos Corporation stock logo
GKOS
Glaukos
-$146.37M-$1.65N/AN/AN/A-21.43%-8.59%-6.61%11/3/2025 (Estimated)
Penumbra, Inc. stock logo
PEN
Penumbra
$14.01M$3.7671.9954.192.4011.54%11.55%8.76%10/29/2025 (Estimated)
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$412M$2.1617.3018.661.03N/AN/AN/AN/A
Solventum Corporation stock logo
SOLV
Solventum
$478M$2.1633.7413.271.774.52%29.93%6.65%11/6/2025 (Estimated)

Latest GKOS, SNN, SOLV, and PEN Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/7/2025Q2 2025
Solventum Corporation stock logo
SOLV
Solventum
$1.45$1.69+$0.24$0.51$2.12 billion$2.16 billion
7/30/2025Q2 2025
Glaukos Corporation stock logo
GKOS
Glaukos
-$0.26-$0.24+$0.02-$0.34$115.49 million$124.12 million
7/29/2025Q2 2025
Penumbra, Inc. stock logo
PEN
Penumbra
$0.81$0.86+$0.05$1.15$327.37 million$339.46 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Glaukos Corporation stock logo
GKOS
Glaukos
N/AN/AN/AN/AN/A
Penumbra, Inc. stock logo
PEN
Penumbra
N/AN/AN/AN/AN/A
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
$0.571.53%N/A26.39%N/A
Solventum Corporation stock logo
SOLV
Solventum
N/AN/AN/AN/AN/A

Latest GKOS, SNN, SOLV, and PEN Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
8/5/2025
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
semi-annual$0.28502.1%10/3/202510/3/202511/7/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Glaukos Corporation stock logo
GKOS
Glaukos
0.09
5.51
4.69
Penumbra, Inc. stock logo
PEN
Penumbra
0.02
6.75
4.04
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
0.60
3.00
1.40
Solventum Corporation stock logo
SOLV
Solventum
2.14
1.22
0.86

Institutional Ownership

CompanyInstitutional Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
99.04%
Penumbra, Inc. stock logo
PEN
Penumbra
88.88%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
25.64%
Solventum Corporation stock logo
SOLV
Solventum
N/A

Insider Ownership

CompanyInsider Ownership
Glaukos Corporation stock logo
GKOS
Glaukos
5.80%
Penumbra, Inc. stock logo
PEN
Penumbra
4.20%
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
1.00%
Solventum Corporation stock logo
SOLV
Solventum
0.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Glaukos Corporation stock logo
GKOS
Glaukos
78057.35 million54.02 millionOptionable
Penumbra, Inc. stock logo
PEN
Penumbra
4,50039.00 million37.36 millionOptionable
Smith & Nephew SNATS, Inc. stock logo
SNN
Smith & Nephew SNATS
17,349437.98 million433.60 millionOptionable
Solventum Corporation stock logo
SOLV
Solventum
22,000173.39 million173.30 millionOptionable

Recent News About These Companies

Solventum to Participate in Upcoming Investor Conferences
Solventum (NYSE:SOLV) Downgraded by Wall Street Zen to "Buy"
Analysts Set Solventum Corporation (NYSE:SOLV) PT at $85.75
Wall Street Zen Downgrades Solventum (NYSE:SOLV) to Buy
Solventum commences tender offers worth $1.75B

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Glaukos stock logo

Glaukos NYSE:GKOS

$95.38 -1.18 (-1.23%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Penumbra stock logo

Penumbra NYSE:PEN

$271.49 -0.19 (-0.07%)
As of 10:10 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands. In addition, the company provides peripheral embolization products, such as Ruby Coil System consisting of detachable coils for peripheral applications; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers an immersive 3D computer-based technology platform under the real immersive system brand; and neurosurgical tools, such as Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.

Smith & Nephew SNATS stock logo

Smith & Nephew SNATS NYSE:SNN

$37.33 +0.10 (+0.26%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT. The Advanced Wound Management segment includes advanced wound care, advanced wound bioactives, and advanced wound devices businesses. The company was founded in 1856 and is headquartered in Watford, the United Kingdom.

Solventum stock logo

Solventum NYSE:SOLV

$72.83 +0.17 (+0.24%)
As of 10:11 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. The Dental Solutions segment provides a comprehensive suite of dental and orthodontic products including brackets, aligners, restorative cements, and bonding agents. The Health Information Systems provides software solutions including computer-assisted, physician documentation, direct-to-bill and coding automation, classification methodologies, speech, recognition, and data visualization platforms. The Purification and Filtration segment provides purification and filtration technologies including filters, purifiers, cartridges, and membranes. The company was incorporated in 2023 and is based in Saint Paul, Minnesota.